The sulfonylurea controversy: More questions from the heart

Journal of the American College of Cardiology

Volumn 31, Issue 5, 1998, Pages 950-956

  Brady, Peter A ^a   Terzic, Andre ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; SULFONYLUREA DERIVATIVE;

HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HEART; HEART DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; PANCREAS; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; SULFONYLUREA COMPOUNDS;

EID: 0032053572     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00038-2     Document Type: Review

References (107)

1. Uusitupa M, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type-2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologica 1993;36:1175-84.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
3. Holmes DR, Vlietstra RE, Smith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984:53:77C-81C.
4. Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction: analysis of patient subgroups in the thrombolysis in myocardial infarction (TIMI) trial, phase II. Circulation 1992;85:1254-64.
5. Granger C, Califf RM, Young S, et al., for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. J Am Coll Cardiol 1993;21:920-5.
6. Stein B, Weintraub WS, Gebhart SSP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995;91:979-89.
7. Kip K, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW, for the Investigators of the NHLBI PTCA Registry. Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996;94: 1818-25.
8. BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-25.
9. The DCCT Trialists. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
10. Klimt C, Knatternd GL, Meinert CL, Prout TE. A study of the effects of hypoglycemic agents in vascular complications in patients with adult-onset diabetes. Diabetes 1970;19:747-830.
11. Ashcroft S, Ashcroft FM. The sulfonylurea receptor. Biochim Biophys Acta 1992;1175:45-59.
12. + channels: regulation by intracellular nucleotides and potassium opening drugs. Am J Physiol 1995;38:C525-45.
13. ATP blockade in type II diabetes and preconditioning in cardiovascular disease: time for reconsideration. Circulation 1996;94:2297-301.
14. Loubatiere A. The hypoglycemic sulfonamides: history and development of the problem from 1942 to 1955. Ann NY Acad Sci 1957;71:4-11.
15. Seltzer H. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972;21:976-9.
16. Paasikivi J. Long-term tolbutamide treatment after myocardial infarction: a clinical and biochemical study of 178 patients without overt diabetes. Acta Med Scand Suppl 1970;507:1-82.
17. Ohneda A, Maruhama Y, Itabashi H, et al. Vascular complications and long-term administration of oral hypoglycemic agents in patients with diabetes mellitus. Tohoku J Exp Med 1978;124:205-22.
18. Groop L. Sulfonylureas in NIDDM. Diabetes Care 1992;15:737-54.
19. Gerich J. Oral hypoglycemic agents. N Engl J Med 1989;321:1231-45.
20. Bryan J, Aguilar-Bryan L. The ABCs of ATP-sensitive potassium channels: more pieces of the puzzle. Curr Opin Cell Biol 1997;9:553-9.
21. Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes 1996;104: 1-9.
22. + channel in cardiac muscle. Nature 1983;305: 147-9.
23. Polonsky K. The beta-cell in diabetes: from molecular genetics to clinical research. Diabetes 1995;44:705-17.
24. + channels in pancreatic B-cells. Nature 1984;311:271-3.
25. + channel. Diabetes Rev 1996;4:177-90.
26. + channels in the control of glucose-induced electrical activity in pancreatic B-cells. Pflugers Arch Eur J Physiol 1990;416:568-72.
27. Ashcroft F. Sweet news for hypoglycemic babies. Nature Med 1996;2: 1301-2.
28. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995;268:423-6.
29. + channels. J Biol Chem 1988;263:7933-6.
30. + channels in cardiac muscle by the sulfonylurea drug glibenclamide. J Pharmacol Exp Ther 1992;261:540-5.
31. + channel current in atrial myocytes of guinea pig heart. Jpn J Pharmacol 1990;54:473-7.
32. ATP channels by glibenclamide in rat ventricular myocytes. J Cardiovasc Electrophysiol 1992;4:38-47.
33. + loss during hypoxia, ischemia, and metabolic inhibition in mammalian ventricle. Circ Res 1991;69:623-37.
34. Nichols CG, Lederer WJ. Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am J Physiol 1991;261:H1675-86.
35. Findlay I. Interactive regulation of the ATP-sensitive potassium channel of cardiac muscle. J Cardiovasc Pharmacol 1994;24:S6-S11.
36. + channels. Cardiovasc Drugs Ther 1993;7:499-505.
37. ATP channel opening in patches from guinea-pig cardiomyocytes. J Physiol 1996;492: 395-404.
38. + channels by adenylate kinase activity. J Biol Chem 1996;271:31903-8.
39. + channels: basis for channel opening. J Gen Physiol 1998;111:381-94.
40. Murray C, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay in lethal injury in ischemic myocardium. Circulation 1986;74:1124-36.
41. Gross GJ. ATP-sensitive potassium channels and myocardial preconditioning. Basic Res Cardiol 1995;90:85-8.
42. Ovize M, Kloner RA, Hale S, et al. Coronary cyclic flow variations "precondition" ischemic myocardium. Circulation 1992;85:779-89.
43. + channels to Al receptors by G proteins in rat ventricular myocytes. Am J Physiol 1990;259:820-6.
44. Grover G, Sleph PG, Dzwonczyk S. Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors. Circulation 1992;86: 1310-6.
45. + channels by antagonizing ATP-dependent gating. Neuron 1994;12:885-93.
46. Grover GJ. Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia. J Cardiovasc Pharmacol 1994;24: S18-27.
47. Edwards G, Weston AH. The pharmacology of ATP-sensitive potassium channels. Ann Rev Pharmacol Toxicol 1993;33:597-637.
48. + channel openers and 'natural' cardioprotection. Trends Pharmacol Sci 1992;13:269-72.
49. 2+ waves: a laser confocal microscopy study. Am J Physiol 1996;270:H1384-9.
50. Lopez RJ, Jahangir R, Jahangir A, Shen WK, Terzic A. Potassium channel openers prevent potassium-induced calcium loading of cardiac cells: possible implications in cardioplegia. J Thorac Cardiovas Surg 1996;112:820-31.
51. Gross G, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-33.
52. + channel blocker, inhibits cardiac cAMP-activated Cl- conductance. Circ Res 1995;77:417-23.
53. Parkinson SJ, Alekseev AE, Gomez LA, Wagner F, Terzic A, Waldman SA. Interruption of Escherichia coli heat-stable enterotoxin-induced guanylyl cyclase signaling and associated chloride current in human intestinal cells by 2-chloroadenosine. J Biol Chem 1997;272:754-8.
54. + current in the human neuroblastoma cell line SH-SY5Y. Neurosci Lett 1992;135:37-40.
55. Chopra LC, Twort CH, Ward JP. Direct action of BRL 38227 and glibenclamide on intracellular calcium stores in cultured airway smooth muscle of rabbit. Br J Pharmacol 1992;105:259-60.
56. Cook GA. The hypoglycemic sulfonylureas glyburide and tolbutamide inhibit fatty acid oxidation by inhibiting carnitine palmitoyltransferase. J Biol Chem 1987;262:4968-72.
57. Kloner R, Yellon D. Does ischemic preconditioning occur in patients? J Am Coll Cardiol 1994;24:1133-42.
58. Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW Jr, Herrman HC, Laskey WK. Adaption to ischemia during percutaneous transluminal coronary angioplasty: clinical, hemodynamic, and metabolic features. Circulation 1990;82:2266-8.
59. Cribier A, Korsatz L, Koning R, et al. Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty. J Am Coll Cardiol 1992;20:578-86.
60. + channel blocker. Circulation 1994;90:700-5.
61. Matsuda Y, Ogawa H, Moritani K, et al. Effects of the presence or absence of preceding angina pectoris on left ventricular function after acute myocardial infarction. Am Heart J 1984;108:955-8.
62. Muller D, Topol EJ, Califf RM, et al. Relationship between antecedent angina pectoris and short term prognosis after thrombolytic therapy for acute myocardial infarction. Am Heart J 1990;119:224-31.
63. Kloner R, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI-4: a clinical correlate to preconditioning? Circulation 1995;91:37-45.
64. Heberden W. A letter to Dr Heberden concerning the angina pectoris: an account of the dissection of one who had been troubled with that disorder. Read at the college Nov 17, 1772. Med Trans Publ Coll Physicians Lond 1785;3:1-11.
65. Marber M, Joy MD, Yellon DM. Is warm up in angina ischemic preconditioning? Br Heart J 1994;72:213-5.
66. Maybaum S, Ilan M, Mogilevsky J, Tzivoni D. Improvement in ischemic parameters during repeated exercise testing: a possible model for myocardial preconditioning. Am J Cardiol 1996;78:1087-91.
67. Cleveland JC, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: two paradoxes revisited. Circulation 1997;96:29-32.
68. Perrault L, Menasche P, Bel A, et al. Ischemic preconditioning in cardiac surgery: a word of caution. J Thorac Cardiovasc Surg 1996;112:1378-86.
69. Barbash G, White HD, Modan M, Van de Werf F. Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol 1992;20:36-41.
70. Behar S, Reicher-Reiss H, Abinader E, et al. The prognostic significance of angina pectoris preceding the occurrence of a first acute myocardial infarction in 4166 consecutive hospitalized patients. Am Heart J 1992;123: 1481-6.
71. Hearse D. Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Cardiovasc Res 1995;30: 1-17.
72. Gibbons R, Christian TF, Hopfenspirger M, Hodge DO, Bailey KR. Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction: implications for the design of randomized trials of acute intervention. J Am Coll Cardiol 1994;24:616-23.
73. + channels during metabolic stress in cardiac muscle. J Pharmacol Exp Ther 1993;266:456-467.
74. + channels. Am J Physiol 1996;271:H2710-6.
75. + channels towards sulfonylureas. Circ Res 1998;82:272-8.
76. + channels toward intracellular nucleoside diphosphates. Neuron 1994;12:1049-58.
77. ATP channels: operative state-dependent regulation by a nucleoside diphosphate. Pflugers Archiv Eur J Physiol 1996;431:800-2.
78. 2+ loading in cardiomyocytes. Eur J Pharmacol 1996;308:343-9.
79. + channel current in ischemic arrhythmias. Cardiovasc Drugs Ther 1993;7:521-6.
80. Wilde A, Janse MJ. Electrophysiological effects of ATP sensitive potassium channel modulation: implications for arrhythmogenesis. Cardiovasc Res 1994;28:16-24.
81. + current. Circ Res 1996;79:208-21.
82. Liu B, Goylan F, McCullough JR, Vassalle M. Electrophysiological and antiarrhythmic effects of the K-channel opener, BRL 34915, in cardiac Purkinje fibres. Drug Dev Res 1988;14:123-39.
83. Lathrop D, Nanasi PP, Varro A. In vitro cardiac models of dog Purkinje fibre triggered activity: effects of nicorandil. Br J Pharmacol 1990;99:119-23.
84. + current activated by pinacidil. Circ Res 1991;68:1127-37.
85. Billman GE, Avendano CE, Halliwill JR, Burroughs JM. The effects of the ATP-dependent potassium channel antagonist, glyburide, on coronary blood flow and susceptibility to ventricular fibrillation in unanesthetized dogs. J Cardiovasc Pharmacol 1993;21:197-204.
86. + loss and arrhythmias in rat heart: effects of glibenclamide, a sulfonylurea. Circ Res 1990;66:478-85.
87. Cacciapuoti F, Spiezia R, Bianchi U, Lama D, D'Avino M, Varricchio M. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am J Cardiol 1991;67: 843-7.
88. + channel blockers on the action potential shortening in hypoxic and ischemic myocardium. Br J Pharmacol 1991;103:1019-26.
89. + channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991;69:571-81.
90. + channel on ECG ST segment elevation during a bout of myocardial ischemia: a study on epicardial mapping in dogs. Circulation 1993;88:1845-51.
91. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989;69:1049-169.
92. Lomuscio A, Vergani D, Marano L, Castagnone M, Fiorentini C. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction. Coronary Artery Dis 1994;5:767-71.
93. Airaksinen K, Huikuri HV. Antiarrhythmic effect of repeated coronary occlusion during balloon angioplasty. J Am Coll Cardiol 1997;29:1035-8.
94. Kondo T, Kubota I, Tachibana H, Yamaki M, Tomoike H. Glibenclamide attenuates peaked T wave in early phase of myocardial ischemia. Cardiovasc Res 1996;31:683-7.
95. Vegh A, Papp JG, Szekeres L, Parratt JR. Are ATP-sensitive potassium channels involved in the pronounced antiarrhythmic effects of preconditioning? Cardiovasc Res 1993;27:638-43.
96. Inagaki N, Gonoi T, Clement JP, et al. Reconstitution of the IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 1995;270: 1166-70.
97. + channels. Neuron 1996;16:1011-7.
98. Clement JP, Kunjilwar K, Gonzalez G, et al. Association and stoichiometry of K-ATP channel subunits. Neuron 1997;18:827-38.
99. + channel. Mol Cell Biol 1998;18:1652-9.
100. + channels in the absence of the sulfonylurea receptor. Nature 1997;387:179-83.
101. + channel. J Biol Chem 1996;271:24321-4.
102. + channel. J Physiol 1997;499:715-20.
103. + channel behavior. J Membrane Biol 1997;159:161-8.
104. Ammala C, Moorhouse A, Gribble F, et al. Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels. Nature 1996;379:545-8.
105. ATP channel. Proc Natl Acad Sci USA 1997;94:11969-73.
106. Garratt KM, Hassinger N, Grill DE, Terzic A, Srivatsa SS, Holmes DR. Sulfonylurea drug use is associated with increased early mortality during direct coronary angioplasty for acute myocardial infarction among diabetic patients [abstract]. J Am Coll Cardiol 1997;29 Suppl A:493A.
107. Brady PA, Al-Suwaidi J, Kopecky SL, Terzic A. Sulfonylurea and mortality in diabetic patients with myocardial infarction. Circulation 1998;97:709-10.